MMP9 and plasma cell myeloma: For example, Ritchie et al. showed that Roneparstat, a well-known HPSE inhibitor, was able to inhibit HPSE activity and downregulate proangiogenic factor expression, such as VEGF, but also regulate MMP-9 expression in myeloma model in vivo [25].